[FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi
Hitoshi
H
D000208:Acute Disease; D002986:Clinical Trials as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology*; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology
D004791:Enzyme Inhibitors; D007191:Indazoles; C543891:KW 2449; D010879:Piperazines; D011799:Quinazolines; C464670:tandutinib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D019311:Staurosporine; C059539:midostaurin